CellWell record HH-220734
Low baseline HbA1c and reduced eGFR are associated with relatively unfavorable body recomposition after SGLT2 inhibitor therapy in type 2 diabetes
Mizuki Gobaru; Nao Hasuzawa; Noboru Kurinami; Nobuhiko Wada; Lixiang Wang; Ayako Nagayama; Kenji Ashida; Yoshinori Moriyama; Hideaki Jinnouchi; Masatoshi Nomura
2026
In plain language
In type 2 diabetes, lower baseline HbA1c and reduced kidney function predicted less favorable muscle-to-fat balance changes during SGLT2 inhibitor therapy.
- Evidence
- Emerging
- Design
- Observational study
Cite this record: https://thecellwell.org/studies/HH-220734
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.